- Thinly-traded nano cap Agenus (NASDAQ:AGEN +11.3%) jumps on triple normal volume in response to the successful outcome of the Phase 3 clinical trial of GlaxoSmithKline's (GSK +2.4%) shingles vaccine candidate, HZ/su. One of the key components of the vaccine's adjuvant system, AS01B, is Agenus' QS-21 Stimulon adjuvant.
- Previously: Glaxo shingles vaccine candidate successful in Phase 3 study (Dec. 18, 2014)